Advertisement

Amgen Inc. AMGN

Set alert

Price alert · AMGN

All alert types
465.45 USD -0.56 -0.12%

At close · Nov 2

465.45 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
465.51 × 1
Ask
465.66 × 1
461.00 Day range 469.00
292.12 52-week range 475.65
YTD
+42.20%
1 year
+55.97%
Open
463.13
Prev close
466.01
Mkt cap
251.64B
Vol
3.17M
Avg vol
2.80M
EPS
16.10
P/E
28.91
Div yield
2.16%
More statistics
Low
461.00
High
469.00
Forward P/E
19.01
Beta
0.42
Short ratio
4.35
Inst. own
85.13%
Dividend
10.08
Ex-div date
Nov 19, 2026
Earnings
Nov 3, 2026
50-d avg
419.96
200-d avg
374.79
1y target
397.32

5m chart

Chart tools
Interval

Built from the cached five-day intraday bars.

Signals (129)
NameTimeAgo
SMA: BearishNov 2, 3:55 PM28 minutes ago
SMA: BearishNov 2, 3:50 PM33 minutes ago
MACD: Sell SignalNov 2, 3:50 PM33 minutes ago
SMA: BullishNov 2, 3:45 PM38 minutes ago
MACD: Buy SignalNov 2, 3:45 PM38 minutes ago
SMA: BearishNov 2, 3:30 PM53 minutes ago
MACD: Sell SignalNov 2, 3:25 PM58 minutes ago
MACD: Buy SignalNov 2, 2:55 PM1 hour ago
SMA: BullishNov 2, 2:40 PM1 hour ago
SMA: BearishNov 2, 2:35 PM1 hour ago
SMA: BullishNov 2, 2:20 PM2 hours ago
SMA: BearishNov 2, 2:15 PM2 hours ago
SMA: BullishNov 2, 1:45 PM2 hours ago
SMA: BearishNov 2, 1:30 PM2 hours ago
SMA: BullishNov 2, 1:25 PM2 hours ago
MACD: Sell SignalNov 2, 1:20 PM3 hours ago
SMA: BearishNov 2, 1:00 PM3 hours ago
SMA: BullishNov 2, 12:45 PM3 hours ago
SMA: BearishNov 2, 12:40 PM3 hours ago
SMA: BullishNov 2, 11:50 AM4 hours ago
SMA: BullishNov 2, 11:35 AM4 hours ago
SMA: BearishNov 2, 11:30 AM4 hours ago
SMA: BullishNov 2, 11:20 AM5 hours ago
SMA: BearishNov 2, 11:10 AM5 hours ago
SMA: BullishNov 2, 11:00 AM5 hours ago
MACD: Buy SignalNov 2, 10:50 AM5 hours ago
SMA: BullishNov 2, 10:45 AM5 hours ago
SMA: BearishNov 2, 10:00 AM6 hours ago
SMA: BullishNov 2, 9:55 AM6 hours ago
RSI: OversoldNov 2, 9:50 AM6 hours ago
MACD: Sell SignalNov 2, 9:45 AM6 hours ago
SMA: BearishNov 2, 9:35 AM6 hours ago
SMA: BullishNov 2, 9:30 AM6 hours ago
SMA: BearishOct 30, 3:55 PM3 days ago
MACD: Buy SignalOct 30, 3:35 PM3 days ago
SMA: BullishOct 30, 3:30 PM3 days ago
RSI: OversoldOct 30, 3:25 PM3 days ago
RSI: OversoldOct 30, 3:15 PM3 days ago
RSI: OversoldOct 30, 2:35 PM3 days ago
SMA: BearishOct 30, 2:05 PM3 days ago
SMA: BearishOct 30, 2:05 PM3 days ago
SMA: BullishOct 30, 2:00 PM3 days ago
SMA: BullishOct 30, 2:00 PM3 days ago
SMA: BearishOct 30, 1:40 PM3 days ago
SMA: BearishOct 30, 1:40 PM3 days ago
SMA: BullishOct 30, 1:30 PM3 days ago
SMA: BullishOct 30, 1:30 PM3 days ago
SMA: BearishOct 30, 1:10 PM3 days ago
SMA: BearishOct 30, 12:50 PM3 days ago
MACD: Sell SignalOct 30, 12:50 PM3 days ago
MACD: Buy SignalOct 30, 12:25 PM3 days ago
SMA: BullishOct 30, 12:15 PM3 days ago
SMA: BullishOct 30, 12:10 PM3 days ago
SMA: BearishOct 30, 11:40 AM3 days ago
SMA: BearishOct 30, 11:30 AM3 days ago
SMA: BullishOct 30, 11:25 AM3 days ago
SMA: BearishOct 30, 11:20 AM3 days ago
SMA: BullishOct 30, 10:45 AM3 days ago
MACD: Sell SignalOct 30, 10:20 AM3 days ago
SMA: BearishOct 30, 10:05 AM3 days ago
RSI: OverboughtOct 30, 9:30 AM3 days ago
SMA: BullishOct 29, 3:05 PM4 days ago
SMA: BearishOct 29, 2:50 PM4 days ago
SMA: BullishOct 29, 2:05 PM4 days ago
SMA: BullishOct 29, 2:00 PM4 days ago
MACD: Buy SignalOct 29, 2:00 PM4 days ago
MACD: Sell SignalOct 29, 1:25 PM4 days ago
SMA: BearishOct 29, 1:20 PM4 days ago
SMA: BullishOct 29, 1:15 PM4 days ago
MACD: Buy SignalOct 29, 1:15 PM4 days ago
SMA: BearishOct 29, 1:00 PM4 days ago
SMA: BullishOct 29, 12:45 PM4 days ago
SMA: BearishOct 29, 12:30 PM4 days ago
SMA: BullishOct 29, 12:20 PM4 days ago
SMA: BearishOct 29, 11:25 AM4 days ago
SMA: BearishOct 29, 11:25 AM4 days ago
SMA: BullishOct 29, 11:20 AM4 days ago
MACD: Sell SignalOct 29, 10:30 AM4 days ago
SMA: BearishOct 29, 10:15 AM4 days ago
RSI: OverboughtOct 29, 9:30 AM4 days ago
SMA: BullishOct 28, 3:20 PM5 days ago
MACD: Buy SignalOct 28, 3:20 PM5 days ago
SMA: BullishOct 28, 3:15 PM5 days ago
SMA: BearishOct 28, 2:50 PM5 days ago
MACD: Sell SignalOct 28, 2:50 PM5 days ago
SMA: BullishOct 28, 2:40 PM5 days ago
SMA: BearishOct 28, 2:30 PM5 days ago
SMA: BearishOct 28, 2:30 PM5 days ago
SMA: BullishOct 28, 2:05 PM5 days ago
MACD: Buy SignalOct 28, 1:35 PM5 days ago
SMA: BullishOct 28, 1:25 PM5 days ago
SMA: BearishOct 28, 12:55 PM5 days ago
SMA: BullishOct 28, 12:50 PM5 days ago
SMA: BearishOct 28, 12:00 PM5 days ago
SMA: BearishOct 28, 11:50 AM5 days ago
SMA: BullishOct 28, 11:20 AM5 days ago
MACD: Sell SignalOct 28, 11:10 AM5 days ago
SMA: BearishOct 28, 11:05 AM5 days ago
RSI: OverboughtOct 28, 10:35 AM5 days ago
MACD: Buy SignalOct 28, 9:45 AM5 days ago
SMA: BullishOct 28, 9:40 AM5 days ago
SMA: BullishOct 28, 9:40 AM5 days ago
SMA: BearishOct 28, 9:30 AM5 days ago
SMA: BearishOct 28, 9:30 AM5 days ago
MACD: Sell SignalOct 28, 9:30 AM5 days ago
RSI: OversoldOct 28, 9:30 AM5 days ago
SMA: BullishOct 27, 3:40 PM6 days ago
MACD: Buy SignalOct 27, 3:40 PM6 days ago
SMA: BullishOct 27, 3:35 PM6 days ago
SMA: BearishOct 27, 3:10 PM6 days ago
MACD: Sell SignalOct 27, 3:10 PM6 days ago
MACD: Buy SignalOct 27, 3:05 PM6 days ago
SMA: BullishOct 27, 3:00 PM6 days ago
SMA: BearishOct 27, 1:40 PM6 days ago
SMA: BullishOct 27, 1:35 PM6 days ago
SMA: BearishOct 27, 1:30 PM6 days ago
SMA: BearishOct 27, 1:30 PM6 days ago
SMA: BullishOct 27, 1:10 PM6 days ago
SMA: BearishOct 27, 1:05 PM6 days ago
SMA: BullishOct 27, 12:45 PM6 days ago
SMA: BearishOct 27, 12:40 PM6 days ago
SMA: BullishOct 27, 12:35 PM6 days ago
SMA: BearishOct 27, 12:15 PM6 days ago
RSI: OverboughtOct 27, 12:00 PM6 days ago
SMA: BullishOct 27, 11:50 AM6 days ago
SMA: BearishOct 27, 11:40 AM6 days ago
RSI: OverboughtOct 27, 11:35 AM6 days ago
SMA: BullishOct 27, 11:30 AM6 days ago
SMA: BearishOct 27, 11:25 AM6 days ago

Key statistics

Market cap
251.71B
Enterprise value
295.25B
Trailing P/E
28.92
Forward P/E
19.01
PEG ratio
2.78
Price / sales
6.61
Price / book
21.53
EPS (TTM)
16.10
Beta
0.42
Dividend yield
2.16%
Payout ratio
60.87%
Profit margin
22.95%
Revenue (TTM)
38.09B
Revenue growth
9.50%
Free cash flow
8.65B
Total cash
13.99B
Total debt
57.30B
Return on equity
91.47%
Shares outstanding
540.63M
Short % of float
2.48%
50-day average
419.96
200-day average
374.79

Analyst view

Consensus: hold

Hold
Price target (mean) 397.32 -14.6% downside
Target (low)
225.00
Target (mean)
397.32
Target (high)
500.00
Ratings (0m) 34 12 buy · 17 hold · 5 sell
  • Strong buy4
  • Buy8
  • Hold17
  • Sell3
  • Strong sell2

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate 5.78.

Earnings history

Financials — quick view

All financials
AMGN Revenue — quarterly 10.05B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AMGN Net income — quarterly 2.38B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AMGN EPS — quarterly 4.40
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AMGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Sep 30, 20265.79———
Aug 4, 2026Jun 30, 20265.626.29+0.67+11.92%
Apr 30, 2026Mar 31, 20264.775.15+0.38+7.97%
Feb 3, 2026Dec 31, 20254.735.29+0.56+11.84%
Nov 4, 2025Sep 30, 20255.025.64+0.62+12.35%
Aug 5, 2025Jun 30, 20255.286.02+0.74+14.02%

Upgrades / downgrades

AMGN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 23, 2026OppenheimermainOutperformOutperform
Oct 21, 2026BarclaysmainEqual-WeightEqual-Weight
Oct 13, 2026GuggenheimmainNeutralNeutral
Oct 12, 2026BMO CapitalmainMarket PerformMarket Perform
Oct 12, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 9, 2026UBSmainBuyBuy

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
amgen.com

News

Your note

Sign in to keep a note on AMGN — it syncs with the Stock Master app.

Insider holders

AMGN insider holders
InsiderRelationLatest transactionDateShares held
BRADNER JAMES E.OfficerStock Award(Grant)May 4, 202630,462
BRADWAY ROBERT AChief Executive OfficerStock Award(Grant)May 4, 2026657,299
ECKERT ROBERT ANDREWDirectorStock Award(Grant)May 18, 202626,251
GORDON MURDOOfficerStock Award(Grant)May 4, 202651,837
GRAHAM JONATHAN PGeneral CounselStock Award(Grant)May 4, 202640,211
GRIFFITH PETER H.Chief Financial OfficerStock Award(Grant)May 4, 202650,706

Institution ownership

AMGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.13%49,362,01622.98BJun 29, 2026
Vanguard Capital Management LLC6.52%35,250,10116.41BJun 29, 2026
State Street Corporation5.65%30,560,53714.23BJun 29, 2026
Capital World Investors5.38%29,075,32913.54BJun 29, 2026
Invesco Ltd.3.02%16,320,4467.60BJun 29, 2026
Geode Capital Management, LLC2.90%15,696,0687.31BJun 29, 2026

Fund ownership

AMGN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%17,134,2347.98BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%13,987,1606.51BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF2.27%12,272,3205.71BAug 30, 2026
Invesco QQQ Trust, Series 12.09%11,292,4685.26BSep 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%7,201,5613.35BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%7,005,8963.26BAug 30, 2026
Advertisement